CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL

Industrials SIC 8731 - Services-Commercial Physical & Biological Research NAICS Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) derived NYSE

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

We began operating in 1947 and, since then, have undergone several changes to our business structure. Charles River Laboratories International, Inc. was incorporated in 1994 and we completed our initial public offering in 2000. Our stock is traded on the New York Stock Exchange under the symbol "CRL" and is included in the Standard & Poor's 500 and Composite 1500 indices, the New York Stock Exchange (NYSE) Arca Biotechnology Index, the NYSE Composite and many of the Russell indices, among others. We are headquartered in Wilmington, Massachusetts. Our headquarters mailing address is 251 Ballardvale Street, Wilmington, MA, 01887, and the telephone number at that location is (781) 222-6000. Our Internet site is www.criver.com. Material contained on our Internet site is not incorporated by reference into this Form 10-K. Unless the context otherwise requires, references in this Form 10-K to "Charles River," "we," "us," "the Company" or "our" refer to Charles River Laboratories International, Inc. and its subsidiaries.

Last close 345.37 2026-10-23
Market cap $16.49B 2026-06-27 share count
52-week range 146.19 - 351.21

Valuation FY2025 figures against the last close

P/S4.1x
P/E—
P/FCF31.8x
EV/EBITDA38.0x
Dividend yield—
Diluted EPS-2.91

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Europe
  • Canada
  • Asia Pacific
  • Other
Revenue by geography, 5 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 2.1B (53.3%) 53% U.S. Europe, FY2025: 1.1B (27.5%) 27% Europe Canada, FY2025: 501M (12.5%) 12% Canada Asia Pacific, FY2025: 205M (5.1%) 5% Other, FY2025: 64.9M (1.6%) FY2024 U.S., FY2024: 2.2B (55.3%) 55% Europe, FY2024: 1.1B (26.6%) 27% Canada, FY2024: 482.1M (11.9%) 12% Asia Pacific, FY2024: 197M (4.9%) 5% Other, FY2024: 52.8M (1.3%) FY2023 U.S., FY2023: 2.3B (56.8%) 57% Europe, FY2023: 1.1B (26.1%) 26% Canada, FY2023: 487.3M (11.8%) 12% Asia Pacific, FY2023: 200.8M (4.9%) 5% Other, FY2023: 16.8M (0.4%)
Region FY2025FY2024FY2023
U.S. $2.14B $2.24B $2.35B
Europe $1.10B $1.08B $1.08B
Canada $501.0M $482.1M $487.3M
Asia Pacific $205.0M $197.0M $200.8M
Other $64.9M $52.8M $16.8M

As the company reported it, from the “SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue and Long-Lived Assets by Geographic Segment (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B
Cost of revenue ————————$865.6M$757.7M
Gross profit ————————$992.0M$923.7M
SG&A $743.1M$751.0M$747.9M$665.1M$619.9M$528.9M$517.6M$443.9M$371.3M$364.7M
Operating income $25.2M$227.3M$617.3M$651.0M$589.9M$432.7M$351.2M$331.4M$288.3M$237.6M
Interest expense $107.0M$126.3M$136.7M$59.3M$73.9M$86.4M$60.9M$63.8M$29.8M$27.7M
Pre-tax income -$99.5M$93.1M$581.3M$623.0M$480.7M$447.1M$304.1M$281.7M$297.0M$222.9M
Income tax $42.7M$67.8M$100.9M$130.4M$81.9M$81.8M$50.0M$54.5M$171.4M$66.8M
Net income -$144.3M$22.2M$474.6M$486.2M$391.0M$364.3M$252.0M$226.4M$123.4M$154.8M
EPS, basic -2.910.209.279.577.777.355.174.722.603.29
EPS, diluted -2.910.209.229.487.607.205.074.622.543.23
Shares, diluted (wtd. avg.) 49.6M51.6M51.5M51.3M51.4M50.6M49.7M49.0M48.6M48.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $213.8M$194.6M$284.5M$241.2M$246.3M$233.1M$240.0M$197.3M$166.3M$119.9M
Short-term investments ————$1.1M$1.0M$941.0K$885.0K$28.5M$3.8M
Receivables $708.9M$720.9M$780.4M$752.4M$642.9M$617.7M$514.0M$472.2M$430.0M$364.1M
Inventory $299.1M$278.5M$380.3M$255.8M$199.1M$185.7M$160.7M$127.9M$115.0M$95.8M
Total current assets $1.45B$1.40B$1.61B$1.44B$1.27B$1.20B$1.02B$897.8M$826.6M$656.8M
Property, plant and equipment $1.66B$1.60B$1.64B$1.47B$1.29B$1.12B$1.04B$932.9M$782.0M$755.8M
Goodwill $2.76B$2.85B$3.10B$2.85B$2.71B$1.81B$1.54B$1.25B$804.9M$787.5M
Other intangibles $340.0M$723.4M$864.1M$955.3M$1.06B$787.6M$689.4M$610.9M$369.8M$394.4M
Total assets $7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B
Accounts payable $148.8M$140.3M$168.9M$205.9M$198.1M$122.5M$111.5M$66.2M$77.8M$68.5M
Short-term debt $166.0K$155.0K$3.2M$1.3M$101.0K$47.2M$35.5M$28.2M$28.5M$24.6M
Total current liabilities $1.12B$994.1M$1.06B$1.09B$1.03B$839.8M$710.2M$558.2M$463.5M$429.6M
Long-term debt ———————$1.63B$1.09B$1.19B
Total liabilities $3.92B$4.02B$4.54B$4.58B$4.43B$3.35B$3.03B$2.52B$1.87B$1.86B
Retained earnings $1.39B$1.81B$1.89B$1.43B$980.8M$625.4M$280.3M$42.1M$288.7M$165.3M
Total equity $3.16B$3.46B$3.60B$2.98B$2.54B$2.12B$1.64B$1.32B$1.05B$839.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $737.6M$734.6M$683.9M$619.6M$760.8M$546.6M$480.9M$441.1M$318.1M$316.9M
Depreciation and amortisation $403.3M$361.7M$314.1M$303.9M$265.5M$234.9M$198.1M$161.8M$131.2M$126.7M
Stock-based compensation $71.1M$69.9M$72.0M$73.6M$71.5M$56.3M$57.3M$47.3M$44.0M$43.6M
Capital expenditure $219.2M$233.0M$318.5M$324.7M$228.8M$166.6M$140.5M$140.1M$82.4M$55.3M
Investing cash flow -$209.3M-$245.1M-$563.2M-$607.9M-$1.44B-$601.5M-$681.5M-$955.0M-$72.6M-$692.7M
Financing cash flow -$536.7M-$550.9M-$85.5M-$42.4M$672.6M$47.2M$231.9M$558.1M-$208.5M$380.8M
Buybacks $360.7M$119.2M$24.2M$38.7M$40.7M$24.0M$18.1M$13.8M$106.9M$12.3M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001100682-26-000022.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2B 0 2B 4B 6B Revenue, FY2016: 1.7B Gross profit, FY2016: 923.7M Net income, FY2016: 154.8M Revenue, FY2017: 1.9B Gross profit, FY2017: 992M Net income, FY2017: 123.4M Revenue, FY2018: 2.3B Net income, FY2018: 226.4M Revenue, FY2019: 2.6B Net income, FY2019: 252M Revenue, FY2020: 2.9B Net income, FY2020: 364.3M Revenue, FY2021: 3.5B Net income, FY2021: 391M Revenue, FY2022: 4B Net income, FY2022: 486.2M Revenue, FY2023: 4.1B Net income, FY2023: 474.6M Revenue, FY2024: 4B Net income, FY2024: 22.2M Revenue, FY2025: 4B Net income, FY2025: -144.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.68B $1.86B $2.27B $2.62B $2.92B $3.54B $3.98B $4.13B $4.05B $4.02B
Gross profit $923.7M $992.0M — — — — — — — —
Net income $154.8M $123.4M $226.4M $252.0M $364.3M $391.0M $486.2M $474.6M $22.2M -$144.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8731

TickerCompanyMarket capP/ERevenue growth
IQV IQVIA HOLDINGS INC. $46.63B 35.6x 5.9%
INCY INCYTE CORP $23.12B 18.1x 21.2%
MEDP Medpace Holdings, Inc. $18.68B 43.8x 20.0%
ABSI Absci Corp $1.58B — -38.2%
OABI OmniAb, Inc. $677.5M — -29.3%
NRC NRC HEALTH $485.1M 0.4x -4.0%
ONMD OneMedNet Corp $279.2M — 111.4%
MXCT MAXCYTE, INC. $144.5M — -5.7%